The absence of tumorigenicity in homozygous mice with an inactive 2nd RRM domain further supports the notion that developing small-molecule agents to selectively block individual functional domains within RBM5 may provide a therapeutic approach to targeting RBPs that poses a lower risk for developing complications like cancer (e.g., such as in patients treated for brain injury). This evidence concerns the gene RBM5 and cancer.